What’s the current market cap for Vor Biopharma stock?

Vor Biopharma (VOR) has a market cap of $872m as of June 27, 2026.

What is the P/E ratio for Vor Biopharma stock?

The price to earnings (P/E) ratio for Vor Biopharma (VOR) stock is 0 as of June 27, 2026.

Does Vor Biopharma stock pay dividends?

No, Vor Biopharma (VOR) stock does not pay dividends to its shareholders as of June 27, 2026.

When is the next Vor Biopharma dividend payment date?

Vor Biopharma (VOR) stock does not pay dividends to its shareholders.

What is the beta indicator for Vor Biopharma?

Vor Biopharma (VOR) has a beta rating of 1.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Vor Biopharma stock | $VOR Share Price

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Ticker

$VOR

Sector

Health

Primary listing

NASDAQ

Employees

76

Headquarters

Boston, United States

Website

www.vorbio.com

Vor Biopharma Metrics

BasicAdvanced

$872m

-

-$46.32

1.73

-

Bulls say / Bears say

Brokerage Stifel upgraded Vor Biopharma to 'buy' from 'hold', setting a $55 price target and forecasting $5 billion peak sales for telitacicept based on its mechanism and clinical promise. (Reuters via TradingView)

An interim analysis of the Phase 3 TELIGAN trial of telitacicept in IgA nephropathy published in NEJM showed a 55 % relative reduction in proteinuria versus placebo at 39 weeks with stable eGFR, bolstering evidence of its therapeutic potential. (NEJM)

Vor Biopharma ended Q1 2026 with $491.5 million in cash, cash equivalents and marketable securities, projected to fund operations into early 2029, providing a strong liquidity cushion. (GlobeNewswire)

Vor Biopharma reported a Q1 2026 net loss of $219.6 million, driven predominantly by a $188.4 million non-cash change in the fair value of warrant liabilities, highlighting earnings volatility. (SEC 10-Q)

The company used $38.2 million in operating and $263.2 million in investing cash in Q1 2026, reducing its cash balance by $226.6 million in the quarter, intensifying the need for future financing. (SEC 10-Q)

General and administrative expenses increased to $17.6 million in Q1 2026 from $6.6 million a year earlier, reflecting a 167 % surge driven by stock-based compensation and commercial hires ahead of revenues. (SEC 10-Q)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Vor Biopharma

Ticker

Employees

Vor Biopharma Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy $VOR

Lightyear

Legal

Work with us

Bulls say / Bears say

Vor Biopharma/$VOR

About Vor Biopharma

Ticker

Employees

Vor Biopharma Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

What’s the current market cap for Vor Biopharma stock?

What is the P/E ratio for Vor Biopharma stock?

Does Vor Biopharma stock pay dividends?

When is the next Vor Biopharma dividend payment date?

What is the beta indicator for Vor Biopharma?

Bulls say / Bears say